A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin’s lymphomas by Hosing, Chitra et al.
© 2010 Hosing et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Blood Medicine 2010:1 49–55
Journal of Blood Medicine
O r i g i n A L   r e s e A r c H
open access to scientific and medical research
Open Access Full Text Article
49
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
A randomized study comparing chemotherapy 
followed by g-csF alone or in combination with 
gM-csF for mobilization of peripheral blood stem 
cells in patients with non-Hodgkin’s lymphomas
chitra Hosing1  
Mark F Munsell2 
James M reuben3 
Uday Popat1 
Bang-ning Lee3 
Hui gao3 
Martin Körbling1 
elizabeth J shpall1 
Partow Kebriaei1 
Amin Alousi1 
Marcos De Lima1 
John McMannis1 
Muzaffar Qazilbash1 
Paolo Anderlini1 
sergio giralt1 
richard e champlin1 
issa Khouri1
1stem cell Transplantation and 
cellular Therapy, 2Biostatistics, 
3Hematopathology research, The 
University of Texas M.D. Anderson 
cancer center, Houston, TX, UsA
correspondence: chitra Hosing 
Department of stem cell Transplantation 
and cellular Therapy, Unit 423, The 
University of Texas M.D.   Anderson  
cancer center, 1515 Holcombe Blvd., 
Houston, TX 77030, UsA 
Tel +1 713 792 8750 
Fax +1 713 794 4902 
email cmhosing@mdanderson.org
Objective: Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony 
stimulating factor (GM-CSF) are the two most commonly used cytokines for mobilization 
of stem cells in patients undergoing high dose chemotherapy with stem cell support. Both 
cytokines increase the peripheral blood white blood cell count and the stem cell count but there 
are other differences in the stem cell products mobilized by G-CSF versus those mobilized with 
GM-CSF. Generally higher numbers of dendritic cells are mobilized with GM-CSF than by 
G-CSF. The primary objective of this randomized study was to evaluate the safety and efficacy 
of chemotherapy plus G-CSF versus chemotherapy plus G-CSF and GM-CSF in patients with 
B-cell non-Hodgkin’s lymphoma (NHL) who were undergoing chemo-mobilization. Secondary 
objectives were to determine the expression of various dendritic cell subsets in the two groups 
and to determine the incidence of disease progression or relapse at 12 months.
Methods: We prospectively evaluated 84 patients with relapsed NHL who were candidates 
for high dose therapy (HDT). All patients underwent chemo-mobilization using ifosfamide, 
etoposide, and rituximab. All patients were randomized in an adaptive manner to receive either 
G-CSF or G-CSF plus GM-CSF (G+GM) starting 24 hours after completion of chemotherapy 
and continuing until completion of apheresis. The stem cell yield/kg, the number of apheresis 
procedures needed in the two groups, and the toxicity were recorded. We also enumerated den-
dritic cell subsets, myeloid DCs (mDC) and plasmacytoid DCs (pDC), in apheresis products 
and in peripheral blood (PB) samples collected pre-chemotherapy. The data were expressed as 
a percentage of peripheral blood mononuclear cells.
Results: A total of 84 patients were treated. Forty-three patients received G-CSF and 41 received 
G+GM. Both regimens were well tolerated. The median CD34+ cell dose collected was similar in 
the two groups. A total of 54 (G-CSF N = 25 and G+GM N = 29) paired samples from baseline and 
post-apheresis were available for analysis of dendritic cell subsets. There was no significant differ-
ence in the percentages of mDC subsets between baseline and post-apheresis collected with G-CSF 
or G+GM mobilization. However, there was a significant increase in the percentage of pDC subsets 
in the G-CSF alone when compared to the G+GM arm (P = 0.002). Furthermore, the ratio of mDC 
and pDC was significantly lower after mobilization with G-CSF versus G+GM (P = 0.029).
Conclusion: Addition of GM-CSF to G-CSF to the mobilization regimen resulted in lower 
percentages of pDC in the apheresis products when compared to those with G-CSF alone. This 
shifts the mDC/pDC ratio in the apheresis grafts in favor of mDC in the combination arm. 
However, these differences did not seem to impact the clinical outcomes in the two groups. 
(ClinicalTrials.gov Identifier: NCT00499343).
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Introduction
Peripheral blood stem cells (PBSC) are the preferred source 
of stem cells for autologous transplantation because of the 
technical advantage and the shorter time to engraftment. 
Mobilization of CD34+ cells into the peripheral blood can 
be achieved by the administration of filgrastim (G-CSF 
or Neupogen®), sargramostim (GM-CSF or Leukine®), or 
both, either alone or in combination with chemotherapy. 
Both cytokines differ somewhat in the number and com-
position of PBSCs and effector cells mobilized to the 
peripheral blood. Previous studies have shown a correlation 
between clinical outcome and the graft composition.1–4 As 
a single agent, G-CSF mobilizes more CD34+ cells than 
does GM-CSF. Studies using concurrent or sequential 
mobilization with G+GM suggest that the combination of 
the two growth factors is superior to either GM-CSF or 
G-CSF alone in mobilizing CD34+ cells. There are other 
differences in the stem cell product mobilized by G-CSF 
versus those mobilized with GM-CSF. Generally higher 
numbers of dendritic cells are mobilized with GM-CSF 
than by G-CSF.5,6 Dendritic cells (DCs) are important anti-
gen presenting cells that are necessary for priming naïve 
T cells. They play an important role in the development of 
anti-tumor responses. In humans two types of DCs have 
been described: mDC and pDC.
It is unclear if mobilization of higher numbers of 
dendritic cells has any clinical advantage for patients 
undergoing high-dose chemotherapy and autologous PBSC 
transplantation.
The purpose of this randomized study was to evaluate 
the safety and efficacy of chemotherapy plus G-CSF versus 
chemotherapy plus G+GM in patients with B-cell NHL who 
were undergoing chemo-mobilization. Secondary objectives 
were to determine the degree of expression of various 
dendritic cell subsets in the two groups and determine the 
incidence of disease progression or relapse at 12 months in 
the two groups.
Patients and methods
Patients up to 70 years of age with relapsed or primary 
refractory CD20-positive NHL who were to undergo 
autologous stem cell collection for SCT at The University 
of Texas MD Anderson Cancer Center were eligible for this 
prospective study. All patients were required to have adequate 
hematological, renal, and hepatic function and a Zubrod 
performance status of 3. Patients with active infections 
or lymphoma in the central nervous system, prior pelvic 
radiation, more than three prior chemotherapy regimens, and 
more than six cycles of fludarabine-based chemotherapy were 
excluded. Patients had to be at least three weeks from their last 
chemotherapy. All patients provided written informed consent. 
The protocol was reviewed and approved by the Institutional 
Review Board of The University of Texas MD Anderson 
Cancer Center, and the study was reviewed annually by The 
University of Texas MD Anderson Data Safety Monitoring 
Board (DSMB). The data for this analysis were collected from 
the institution’s Department of Stem Cell Transplantation 
database and from patients’ medical records.
chemotherapy
Patients received ifosfamide, 10 g/m2, given by continuous 
intravenous infusion over 72 hours on days 1–3, etoposide, 
150 mg/m2, given intravenously every 12 hours for a total 
of six doses on days 1–3, and rituximab intravenously at 
375 mg/m2 on day 1 and at 1000 mg/m2 on day 8. Patients 
randomized to the G-CSF arm started G-CSF on day +6 at 
6 µg/kg (rounded off to the nearest vial) every 12 hours until 
completion of apheresis. Patients randomized to the G+GM 
arm started G-CSF 6 µg/kg (rounded off to the nearest vial) 
every 12 hours on day +6 along with GM-CSF at 250 µg/m2 
daily (rounded off to the nearest vial) till the completion of 
apheresis.
Peripheral blood stem cell collection
Upon recovery of counts PBSCs were collected using stan-
dard apheresis procedures. Apheresis was started when the 
peripheral blood CD34 counts reached 15 × 104/mL and 
continued till the target CD34+ cell dose of 4 × 106/kg 
was reached. All patients underwent leukapheresis using 
the COBE Spectra cell separator (COBE BCT, Inc., 
Lakewood, CO). Three times the estimated blood volume 
was processed during each collection. Anticoagulant citrate 
dextrose solution was used as an anticoagulant. Calcium was 
given by continuous infusion through the return line. The 
total nucleated cell count and the CD34+ cell concentration 
was measured immediately after completion of apheresis. 
Patients who failed to reach a peripheral blood CD34 count 
of 15 × 104/mL or failed to collect a CD34+ cell dose of 
2 × 106/kg after four apheresis procedures were classified 
as mobilization failures.
graft composition
Dendritic cell subsets, mDC and pDC, were enumerated by 
immunophenotyping. DCs were identified by their lack of Journal of Blood Medicine 2010:1 51
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leukocyte lineage-specific markers, and expression of HLA 
DR, CD11c (mDC) and CD123 (pDC). The expression of 
these molecules in the apheresis product was compared 
with that of PB samples collected pre-chemotherapy 
as baseline. Additionally, the percentage of leukocytes 
expressing these differentiation antigens was compared for 
patients in the G-CSF arm with those in the GM-CSF arm 
by the Mann–Whitney U test; differences were considered 
significant for P  0.05.
Statistical methods
This was a randomized trial to compare chemotherapy 
followed by G-CSF or G+GM for stem cell mobilization. 
The primary objective of the study was to determine the 
efficacy of in vivo purging achieved by rituximab in the 
two groups and to determine the number of apheresis pro-
cedures, total stem cell yield/kg patient body weight, and 
the toxicity profile in the two groups. Secondary objectives 
were to determine the expression of various dendritic cell 
subsets in the two groups and determine the incidence of 
disease progression or relapse at 12 months in the two 
groups.
Treatment success was defined as successful purging of 
stem cell product of monoclonal B-cells and the ability to 
collect 4 × 106 CD34+ cells/kg in four, or less, apheresis 
procedures. As part of the pretreatment evaluation patients 
provided bone marrow (BM)/PB for the measurement of 
monoclonal B-cells by flow cytometry. We assumed that if 
the BM/PB was not involved with monoclonal B-cells then 
the collected product did not have to be re-tested. Initially, 
patients were randomized fairly to the two treatment arms. 
After 40 patients had been randomized, adaptive randomiza-
tion was employed to unbalance the randomization in favor 
of the treatment arm having the higher observed success 
rate. We assumed a beta (1.8, 0.2) prior distribution for the 
treatment success rate in each treatment arm. This prior dis-
tribution has a mean of 0.90 and a standard deviation of 0.17. 
Beginning with the 41st and successive patients we found the 
probability that treatment arm G-CSF had a higher success 
rate than treatment arm G+GM, updating the distributions 
for the treatment success rates with the stem cell yield and 
the flow cytometry data that had accumulated during the 
trial to that point. We then randomized patients to treatment 
arm G-CSF with this probability. We planned to enroll a 
maximum of 100 patients, and we planned to stop the study 
as soon as there was a 0.90 probability that one treatment arm 
had a higher success rate than the other treatment arm.
Results
Between February 2004 and August 2007, 84 consecutive 
patients with relapsed or primary refractory B-cell NHL were 
enrolled in the study. Forty-three patients were randomized 
to G-CSF and 41 patients were randomized to G+GM. In 
October 2007 the DSMB recommended the study be closed 
to new patient accrual, since the predictive probability that 
either treatment arm would be found to have a higher suc-
cess rate than the other with probability more than 0.90 was 
less than 0.02.
Patient demographics are summarized in Table 1. There 
were no statistically significant differences between the two 
treatment groups with regard to demographic or clinical 
characteristics.
Apheresis data
All the apheresis products were negative for monoclonal 
B cells by flow cytometric analysis. Thirty-nine of 43 
patients (90.7% with 90% CI: 82.7–96.6%) in the G-CSF 
arm and 35 of 41 patients (85.4% with 90% CI: 76.0–93.3%) 
in the G+GM arm successfully collected 4 × 106 CD34+ 
cells/kg body weight. The probability that the G-CSF arm 
Table 1 Baseline patient characteristics
 Characteristic G-CSF G-CSF + GM-CSF
N % N %
Total treated 43 51 41 49
Age (years)
  20 to 39 4 9.3 3 7.3
  40 to 59 29 57.4 26 63.5
  60 to 79 10 23.2 12 29.3
Gender
  Male/Female 29/14 67.4/32.6 24/17 58.5/41.5
Histology
  Low grade 4 9.3 7 17.1
  intermediate grade 39 90.7 34 82.9
Ann Arbor stage
  0–1 25 58.1 23 56.1
  1 18 41.9 18 43.9
LDH*
  normal 28 65.1 29 72.5
  normal 15 34.9 11 27.5
Number of prior chemotherapies
  Median (range) 2 (1–4)   2 (1–3)  
Notes: *One patient on the g-csF + gM-csF treatment arm has no data   
on LDH.
Abbreviations: g-csF, granulocyte colony-stimulating factor; gM-csF, granulocyte-
macrophage colony-stimulating factor; LDH, lactate dehydrogenase.Journal of Blood Medicine 2010:1 52
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has a higher success rate than the G+GM arm is 0.778. The 
median CD34+ cell dose collected was 10.34 × 106/kg (range, 
0.14–59) in G-CSF arm and 7.5 × 106/kg (range, 0.79–73.7) 
in the G+GM arm (P = 0.65). Median numbers of apheresis 
procedures required were two in both arms (P = 0.64). 
Collection started a median of 17 days (range, 12–26) from 
the start of chemotherapy in the G-CSF arm and 14 days 
(range, 13–26) in the G+GM arm (P = 0.06). These results 
are summarized in Table 2.
count recovery
The median time to absolute neutrophil count (ANC) of 
0.5 × 109/L was 14 days (range, 0–20) in the G-CSF arm 
and 13 days (range, 0–21) in the G+GM arm (P = 0.05) as 
shown in Table 2.
Toxicity data
No unexpected toxicities were observed. Commonly 
experienced toxicities included bone pain and myalgias 
secondary to cytokine administration, cytopenias related 
to chemotherapy, and febrile neutropenia. No one expe-
rienced grade 4 or 5 toxicity. The most common grade 3 
toxicities that were observed are summarized in Table 3a 
(CTCAE v 3.0).7 The number of patients who experi-
enced a grade 3 adverse event was similar in the G-CSF 
and G+GM group (11 versus 13 patients, respectively; 
P = 0.3) (Table 3b).
Overall and disease-free survival
After a median follow up time of 14.5 months (range, 
0.6–38.5) in the G-CSF arm and 14.0 months (range, 1.1–39.9) 
in the G+GM arm, the 3-year overall survival (OS) was 85% 
(95% CI: 69.5%–100%) and 86.6% (95% CI: 76.2%–98.3%), 
respectively (P = 0.489). The 3-year disease-free survival 
(DFS) was 75.8% (95% CI: 57.9%–99.4%) in the G-CSF 
arm and 77.1% (95% CI: 65.0%–91.5%) in the G+GM arm 
as shown in Figure 1.
The OS for patients with intermediate grade NHL was 
83.7% (95% CI: 72.2%–97.0%) at 3 years. None of the 
patients with low grade NHL died. The DFS for patients with 
intermediate grade NHL was 72.8% (95% CI: 60%–88.4%) 
at 3 years. None of the patients with low grade NHL had 
recurrent disease.
graft composition
A total of 54 patients (25 G-CSF and 29 G+GM) provided 
paired baseline and post-apheresis samples DC subset 
Table 2 Apheresis data
G-CSF  
N = 43
G-CSF + GM-CSF  
N = 41
P 
value
Days from start of  
chemotherapy to  
apheresis Median  
(range)
17 (12–26) 14 (13–26) 0.05
Failure to mobilize 2 3 0.67
Failure to collect  
4 × 106 cD34+ 
cells/kg
2* 2 0.99
no. of apheresis  
needed  
Median (range)
2 (1–6) 2 (1–7) 0.64
cD34+ cells/kg  
Median (range)
10.34 × 106  
(0.14–59)
7.5 × 106  
(0.8–74)
0.65
Anc  0.5 × 109/L  
after mobilization (days) 
Median (range)
14 (0–20) 
 
13 (0–21) 
 
0.06
Notes: *One patient was noncompliant with therapy.
Abbreviations: Anc, absolute neutrophil count;  g-csF, granulocyte colony-
stimulating factor; gM-csF, granulocyte-macrophage colony-stimulating factor.
Table 3a Toxicity data: grade 3 adverse events (cTcAe v 3.0)
Adverse event G-CSF G-CSF/GM-CSF Total
Bone pain 1 0 1
cytokine release  
syndrome
0 2 2
Drug fever 0 1 1
esophagitis 1 0 1
Febrile neutropenia 6 7 13
Fever/infection  
without neutropenia
1 1 2
Muscle weakness  
(generalized)
0 1 1
nausea/vomiting 2 0 2
Thrombocytopenia 1 0 1
Anemia 2 1 3
syncope 0 1 1
Total 14 14 28
Abbreviations: g-csF, granulocyte colony-stimulating factor; gM-csF, granulocyte-
macrophage colony-stimulating factor.
Table 3b number of patients by maximum grade of adverse 
event
Maximum rade G-CSF G + GM Total
3 11 13 24
2 10 15 25
1 19 12 31
Total 40 40 80
Notes: There appear to be no statistically significant differences between treatment 
groups with respect to the number of patients with maximum grade adverse event. 
Fisher’s exact test P-value = 0.2704.Journal of Blood Medicine 2010:1 53
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analysis. There was no significant difference between the 
percentages of mDC subsets in the apheresis products in 
the two arms. However, there was a significant increase 
in the percentage of pDC subsets in the apheresis product 
in the G-CSF arm when compared to G+GM (P = 0.002); 
consequently, there was a significant decrease in the ratio of 
mDC and pDC (mDC/pDC) with G-CSF when compared to 
G+GM (P = 0.029) (Table 4 and Figure 2).
Discussion
Although G-CSF and GM-CSF are widely used for stem 
cell mobilization in normal donors and in patients with 
hematological malignancies who are to undergo an autologous 
stem cell transplant, there is still controversy regarding the 
role of the two cytokines in mobilizing DC cells and their 
subsets. The clinical impact, of either of the two mobilization 
strategies in patients undergoing autologous PBSC transplan-
tation is also unclear. Our study shows that both regimens are 
well tolerated. The most common grade 3 toxicity was febrile 
neutropenia. The stem cell yield, number of apheresis pro-
cedures required to reach a target cell dose of 4 × 106/kg and 
the overall and disease free survival were similar in the two 
groups. Previous studies have shown that GM-CSF when used 
alone or in combination with G-CSF mobilizes more mature 
(CD14-/CD80+ or CD86- cells) and precursor dendritic cells 
when compared to G-CSF alone.5,6,8–12 What is unclear, how-
ever, is whether there is polarization of these dendritic cells 
to myeloid dendritic cells or plasmacytoid dendritic cells and 
its clinical significance. Several groups have reported polar-
ization to pDC cells in normal donors who received G-CSF 
for stem cell mobilization.13–15 In contrast Shaughnessy et al 
did not observe any polarization of DCs by either G-CSF or 
GM-CSF in normal donors, however donors receiving G-CSF 
mobilized more mDC and pDC cells.16 Gazitt et al did not find 
a major difference in the ratio of mDC/pDC cells in the PB 
of patients with NHL mobilized with cyclophosphamide plus 
G-CSF compared with patients mobilized with either cyclo-
phosphamide plus GM-CSF or cyclophosphamide plus GM-
CSF followed by G-CSF.12 Others have reported polarization 
to pDC with G-CSF17–18 or no polarization of DC subsets.19 
Sanchez et al11 found that in patients with acute myelogenous 
leukemia who were mobilized with G-CSF alone, there was 
polarization towards the mDC subset.
Our data show that there was no difference in the total 
numbers of DC cells mobilized in the two groups; how-
ever, we found a polarization towards the pDC subset in 
Table 4 changes in the percentages of mDc, pDc and the mDc/
pDc pre and post mobilization with g-csF or g+gM
Median  
(mean ± SEM)
G-CSF 
N = 25
G+GM  
N = 29
P value
%mDC
Pre 55.6 (49.9 ± 3.53) 56.9 (57.2 ± 2.78) 0.125
Post 17.6 (22.5 ± 2.76) 17.8 (19.3 ± 2.11) 0.633
%pDC
Pre 18.9 (21.6 ± 2.83) 22.5 (22.1 ± 1.84) 0.549
Post 7.6 (9.25 ± 1.32) 4.8 (4.82 ± 0.57) 0.002
mDC/pDCmDC
Pre 2.67 (4.80 ± 1.47) 2.68 (3.53 ± 0.52) 0.924
Post 2.52 (3.72 ± 0.80) 4.02 (7.21 ± 2.30) 0.029
Abbreviations: Dc, dentric cells; g-csF, granulocyte colony-stimulating factor; 
gM, granulocyte-macrophage; seM, standard error of mean.
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Figure 1 Kaplan–Meier overall survival.
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patients mobilized with G-CSF alone. We did not observe 
a survival difference in the two arms of the study at 
least with the short follow-up time of 14 months. On the 
contrary Gazitt et al12 reported that there was a survival 
advantage for patients mobilized with GM-CSF contain-
ing regimens. Similarly Dean et al also found that higher 
numbers of mDC cells and total DCs were significantly 
associated with improved survival.1 These differences may 
be explained by the different patient populations studied 
and whether the evaluations were done on the PB or in 
apheresis products.
Conclusion
Mobilization of peripeheral blood progenitor cells with 
a combination of G-CSF plus GM-CSF results in the 
mobilization of higher numbers of pDC cells. However, this 
did not seem to have any clinical advantage.
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